Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Studer

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Der Urologe. Ausg. A|August 10, 2006
[Standards and perspectives in diagnosis and therapy of bladder carcinoma]C Stief, D Zaak, M Stöckle, et al.
Strahlentherapie|December 1, 1985
Results of curative pion therapy at SINR Greiner, C F von Essen, H Blattmann, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843H J de Voogt, J G Klijn, U Studer, et al.
European Urology|March 31, 1998
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative GroupH J de Voogt, U Studer, F H Schröder, et al.
British Journal of Cancer|December 15, 2004
Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapyG Gruber, J Hess, C Stiefel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)H J Schmoll, R Souchon, S Krege, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Der Urologe. Ausg. A|August 10, 2006
[Standards and perspectives in diagnosis and therapy of bladder carcinoma]C Stief, D Zaak, M Stöckle, et al.
Strahlentherapie|December 1, 1985
Results of curative pion therapy at SINR Greiner, C F von Essen, H Blattmann, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843H J de Voogt, J G Klijn, U Studer, et al.
European Urology|March 31, 1998
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative GroupH J de Voogt, U Studer, F H Schröder, et al.
British Journal of Cancer|December 15, 2004
Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapyG Gruber, J Hess, C Stiefel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)H J Schmoll, R Souchon, S Krege, et al.
Pageof 3